BeiGene Q4 2024 Earnings Report
Key Takeaways
BeiGene posted total revenue of $1.13 billion for Q4 2024, reflecting a 78% increase year-over-year. The company narrowed its GAAP operating loss and achieved positive non-GAAP operating income. The success was primarily driven by BRUKINSA, which led the market in new CLL patient starts in the U.S. and expanded in Europe.
Total revenue for Q4 2024 was $1.13 billion, a 78% increase from Q4 2023.
Net loss per share improved to $0.11 from $0.27 in Q4 2023.
BRUKINSA revenue for Q4 2024 reached $828 million, a 100% increase year-over-year.
The company reaffirmed its guidance for full-year 2025 revenue of $4.9 billion to $5.3 billion.
BeiGene Revenue
BeiGene EPS
BeiGene Revenue by Segment
BeiGene Revenue by Geographic Location
Forward Guidance
BeiGene reaffirmed its full-year 2025 revenue guidance of $4.9 billion to $5.3 billion, with expectations of positive GAAP operating income and cash flow generation.
Positive Outlook
- Continued strong growth of Brukinsa in the U.S. and Europe.
- Expansion of Tislelizumab into new indications and regions.
- Pipeline progress with multiple clinical trial readouts expected in 2025.
- Strategic cost management contributing to narrowing operating losses.
- Positive cash flow from operations expected in FY 2025.
Challenges Ahead
- High R&D and SG&A expenses continue to pressure profitability.
- Ongoing net losses despite revenue growth.
- Regulatory risks associated with new product approvals.
- Competitive pressures in the oncology market.
- Foreign exchange volatility impacting international sales.
Revenue & Expenses
Visualization of income flow from segment revenue to net income